ICMJE DISCLOSURE FORM

Date:		6/	6/3/2022			
Your Name:		W	Wim Boersma			
Manuscript Title:			De adviezen voor de medicamenteuze behandeling van COVID-19 in de tweede lijn: een update			
Manuscript Number (if known):		known): Cli	Click or tap here to enter text.			
contaffer indicate The epidethat	tent of your manuscr cted by the content of cate a bias. If you are author's relationship demiology of hyperte medication is not me	ipt. "Related of the manusce in doubt ab os/activities/insion, you shentioned in the all support for	I" means any relation with for-profit or no cript. Disclosure represents a commitme out whether to list a relationship/activity nterests should be defined broadly. For equal declare all relationships with manufule manuscript.	es/interests listed below that are related to the ot-for-profit third parties whose interests may be not to transparency and does not necessarily /interest, it is preferable that you do so. example, if your manuscript pertains to the acturers of antihypertensive medication, even if		
			tities with whom you have this or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)		
	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	onderste	tie van de nieuwe guideline en de uning van de adviezen worden gelijk gemaakt door een grant van	Click the tab key to add additional rows.		
2	Cuanta an	N.	Time frame: past 36 month	S		
2	Grants or contracts from any entity (if not indicated in item #1 above).	None				
3	Royalties or licenses	⊠ None				

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	None None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	None Non	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None None	

			e all entities with whom you have this ionship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)		
11	Stock or stock options		None			
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services		None			
13	Other financial or non-financial interests		None			
Plea ⊠	Please place an "X" next to the following statement to indicate your agreement:					